[go: up one dir, main page]

WO2008009960A3 - Anticorps diriges contre la testosterone - Google Patents

Anticorps diriges contre la testosterone Download PDF

Info

Publication number
WO2008009960A3
WO2008009960A3 PCT/GB2007/002764 GB2007002764W WO2008009960A3 WO 2008009960 A3 WO2008009960 A3 WO 2008009960A3 GB 2007002764 W GB2007002764 W GB 2007002764W WO 2008009960 A3 WO2008009960 A3 WO 2008009960A3
Authority
WO
WIPO (PCT)
Prior art keywords
testosterone
light chain
sequences
heavy
antibodies directed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2007/002764
Other languages
English (en)
Other versions
WO2008009960A9 (fr
WO2008009960A2 (fr
Inventor
Ian Broadbent
Keith Charlton
Andrew Porter
Gillian Strachan
Andrew Kenyon
Lain Mcewan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Aberdeen
Haptogen Ltd
Original Assignee
University of Aberdeen
Haptogen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Aberdeen, Haptogen Ltd filed Critical University of Aberdeen
Publication of WO2008009960A2 publication Critical patent/WO2008009960A2/fr
Publication of WO2008009960A9 publication Critical patent/WO2008009960A9/fr
Publication of WO2008009960A3 publication Critical patent/WO2008009960A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne des anticorps dirigés contre la testostérone stéroïde et les molécules associées ainsi que l'utilisation desdits anticorps. En particulier, dans certains modes de réalisation, l'invention concerne des anticorps monoclonaux entièrement humains dirigés contre la testostérone et les molécules associées. Dans d'autres modes de réalisation, l'invention concerne des séquences nucléotidiques codant pour et des séquences d'acides aminés comprenant des molécules d'immunoglobuline à chaînes lourdes et légères, notamment des séquences correspondant aux séquences de chaînes lourdes et légères contiguës couvrant les les régions de charpente et/ou les régions de détermination de la complémentarité (CDR), spécifiquement de FR1 à FR4 ou de CDR1 à CDR3.
PCT/GB2007/002764 2006-07-21 2007-07-20 Anticorps diriges contre la testosterone Ceased WO2008009960A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0614568.4A GB0614568D0 (en) 2006-07-21 2006-07-21 Anti-testosterone antibodies
GB0614568.4 2006-07-21

Publications (3)

Publication Number Publication Date
WO2008009960A2 WO2008009960A2 (fr) 2008-01-24
WO2008009960A9 WO2008009960A9 (fr) 2008-05-29
WO2008009960A3 true WO2008009960A3 (fr) 2008-07-10

Family

ID=36998533

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2007/002764 Ceased WO2008009960A2 (fr) 2006-07-21 2007-07-20 Anticorps diriges contre la testosterone

Country Status (2)

Country Link
GB (1) GB0614568D0 (fr)
WO (1) WO2008009960A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2681917A1 (fr) * 2007-03-27 2008-10-02 Christopher Hovens Procedes et compositions pour le traitement du cancer de la prostate
AU2009279378A1 (en) * 2008-08-08 2010-02-11 Niall Corcoran Biological applications of steroid binding domains
ITFI20110140A1 (it) * 2011-07-18 2013-01-19 In Fieri S R L Composizione ad uso topico per il trattamento delle alopecie
WO2014120975A1 (fr) 2013-02-01 2014-08-07 California Institute Of Technology Immunocontraception à médiation par un anticorps
US10966414B2 (en) 2015-05-26 2021-04-06 California Institute Of Technology Population control using engineered translocations
US12157883B2 (en) 2017-05-05 2024-12-03 California Institute Of Technology DNA sequence modification-based gene drive
CN109030811A (zh) * 2018-05-31 2018-12-18 湖南远璟生物技术有限公司 一种睾酮酶结合物的制备方法
US11965172B2 (en) 2018-11-05 2024-04-23 California Institute Of Technology DNA sequence modification-based gene drive
KR102350655B1 (ko) * 2020-10-13 2022-01-12 인센 주식회사 테스토스테론-특이적 어피바디 및 이의 용도
CN115521920B (zh) * 2022-08-16 2023-06-06 江南大学 一株丙酸睾丸素单克隆抗体杂交瘤细胞株及其应用
CN118754983B (zh) * 2024-06-20 2025-04-08 无锡傲锐东源生物科技有限公司 一种睾酮夹心法兔单克隆抗体及其应用
CN118772273B (zh) * 2024-08-15 2025-03-07 无锡傲锐东源生物科技有限公司 一种睾酮夹心法兔单克隆抗体mAb1及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999012974A1 (fr) * 1997-09-05 1999-03-18 Orion-Yhtymä Oyj Anticorps monoclonaux se liant au testosterone

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999012974A1 (fr) * 1997-09-05 1999-03-18 Orion-Yhtymä Oyj Anticorps monoclonaux se liant au testosterone

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL [online] 11 July 2000 (2000-07-11), "Synthetic construct HCV non-structural protein 4A single chain Fv antibody mRNA, complete cds.", XP002465158, retrieved from EBI accession no. EMBL:AF271151 Database accession no. AF271151 *
DATABASE EMBL [online] 24 December 2000 (2000-12-24), "602144348F1 NIH_MGC_48 Homo sapiens cDNA clone IMAGE:4297954 5', mRNA sequence.", XP002465159, retrieved from EBI accession no. EMBL:BF663230 Database accession no. BF663230 *
DATABASE Geneseq [online] 23 July 1998 (1998-07-23), "Light chain of a human antibody.", XP002465157, retrieved from EBI accession no. GSP:AAW53585 Database accession no. AAW53585 *
DATABASE USPTO Proteins [online] 13 June 2005 (2005-06-13), "Sequence 89 from patent US 6903194.", XP002465156, retrieved from EBI accession no. USPOP:AAY78242 Database accession no. AAY78242 *
HEMMINKI A ET AL: "Fine tuning of an anti-testosterone antibody binding site by stepwise optimisation of the CDRs", IMMUNOTECHNOLOGY, ELSEVIER SCIENCE PUBLISHERS BV, NL, vol. 4, no. 1, June 1998 (1998-06-01), pages 59 - 69, XP004127387, ISSN: 1380-2933 *
JANA C K ET AL: "Antibody binding characteristics of geometrical isomers of testosterone 3-(O-carboxymethyl)oxime - Study of the characteristics of antibodies against 17alpha-hydroxyprogesterone and testosterone and of their evolution with time", STEROIDS: STRUCTURE, FUNCTION, AND REGULATION, ELSEVIER SCIENCE PUBLISHERS, NEW YORK, NY, US, vol. 64, no. 3, March 1999 (1999-03-01), pages 228 - 232, XP004172198, ISSN: 0039-128X *

Also Published As

Publication number Publication date
GB0614568D0 (en) 2006-08-30
WO2008009960A9 (fr) 2008-05-29
WO2008009960A2 (fr) 2008-01-24

Similar Documents

Publication Publication Date Title
WO2008009960A3 (fr) Anticorps diriges contre la testosterone
WO2008112004A3 (fr) ANTICORPS DIRIGÉS CONTRE αVβ6 ET LEURS UTILISATIONS
WO2005016111A3 (fr) Anticorps diriges vers l'hormone parathyroide et leurs utilisations
WO2004050850A3 (fr) Anticorps diriges contre la phospholipase a2 et utilisations
WO2007120693A3 (fr) AGENTS DE LIAISON CIBLÉS, DIRIGÉS CONTRE L'uPAR, ET UTILISATIONS
WO2006130458A3 (fr) Anticorps diriges contre cd20 et leurs utilisations
WO2006039258A3 (fr) Anticorps diriges contre la parathormone
WO2006071441A3 (fr) Anticorps dirigés contre la gpnmb et leurs utilisations
WO2006081139A3 (fr) Anticorps diriges contre interleukine-1 beta
TW200634027A (en) Antibodies directed to angiopoietin-2 and uses thereof
WO2005118635A3 (fr) Anticorps anti-cd3 et leurs methodes d'utilisation
WO2007070432A3 (fr) Proteines de liaison specifiques des facteurs de croissance analogues a l'insuline et utilisations de celles-ci
WO2008133641A3 (fr) Anticorps dirigés contre la gpnmb et leurs utilisations
WO2006052591A3 (fr) Anticorps anti-properdine et procédé de fabrication et d'utilisation de ceux-ci
WO2006104978A3 (fr) Anticorps dirigés contre les antigènes majeurs de la ténascine
WO2007109307A3 (fr) Anticorps dirigés contre la protéine 4 du type angiopoïétine et utilisations de ceux-ci
NZ601342A (en) Antibodies that bind il-4 and/or il-13 and their uses
WO2004084823A3 (fr) Anticorps contre l'antigene de lymphocytes t, du domaine d'immunoglobuline et du domaine 1 de mucine (tim-1) et leurs utilisations
WO2004050683A8 (fr) Anticorps agissant sur le facteur de necrose des tumeurs (tnf) et leurs utilisation
WO2004016769A3 (fr) Anticorps diriges contre la proteine chimioattractive monocytaire 1 (mcp-1) et leurs utilisations
WO2006055638A3 (fr) Anticorps monoclonaux entierement humains diriges contre l'il-13
EP2548583A3 (fr) Methode de traitement du cancer de l'ovaire et du rein utilisant des anticorps diriges contre l'antigene a domaine 1 de mucine et a domaine immunoglobuline des lymphocytes t (tim-1)
WO2007065037A3 (fr) Anticorps dirigés contre mmp-13 (collagénase-3) et leurs utilisations
NZ600051A (en) Method of providing disease-specific binding molecules and targets

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07766325

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07766325

Country of ref document: EP

Kind code of ref document: A2